scholarly journals Current and future issue of molecular target therapy in hematological malignancy

2010 ◽  
Vol 25 (2) ◽  
pp. 126-133
Author(s):  
Noriyasu Fukushima ◽  
Shinya Kimura
Keyword(s):  
Hematological Malignancy ◽  
Target Therapy ◽  
Molecular Target ◽  
Future Issue ◽  
Molecular Target Therapy

scholarly journals Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor

2013 ◽  
Vol 14 (1) ◽  
pp. 15-26 ◽  
Author(s):  
Christian Rolfo ◽  
Luis E Raez ◽  
Antonio Russo ◽  
Noemí Reguart ◽  
Rosario García Campelo ◽  
...  
Keyword(s):  
Bone Metastasis ◽  
Target Therapy ◽  
Molecular Target ◽  
Molecular Target Therapy ◽  
New Era

Possible molecular target therapy with rapamycin in MDS

2006 ◽  
Vol 47 (5) ◽  
pp. 907-911
Author(s):  
Yasuhiro Maeda ◽  
Terufumi Yamaguchi ◽  
Yasuki Hijikata ◽  
Toshiaki Matsuoka ◽  
Miyako Tanaka ◽  
...  
Keyword(s):  
Target Therapy ◽  
Molecular Target ◽  
Molecular Target Therapy

scholarly journals Current Multimodality Treatments against Brain Metastases from Renal Cell Carcinoma

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 2875
Author(s):  
Yoshiyuki Matsui
Keyword(s):  
Renal Cell Carcinoma ◽  
Brain Metastasis ◽  
Cell Carcinoma ◽  
Immune Checkpoint ◽  
Renal Cell ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Target Therapy ◽  
Molecular Target ◽  
Molecular Target Therapy

In patients with renal cell carcinoma, brain metastasis is generally one of the poor prognostic factors. However, the recent introduction of molecular target therapy and immune checkpoint inhibitor has remarkably advanced the systemic treatment of metastatic renal cell carcinoma and prolonged the patients’ survival. The pivotal clinical trials of those agents usually excluded patients with brain metastasis. The incidence of brain metastasis has been increasing in the actual clinical setting because of longer control of extra-cranial disease. Brain metastasis subgroup data from the prospective and retrospective series have been gradually accumulated about the risk classification of brain metastasis and the efficacy and safety of those new agents for brain metastasis. While the local treatment against brain metastasis includes neurosurgery, stereotactic radiosurgery, and conventional whole brain radiation therapy, the technology of stereotactic radiosurgery has been especially advanced, and the combination with systemic therapy such as molecular target therapy and immune checkpoint inhibitor is considered promising. This review summarizes recent progression of multimodality treatment of brain metastasis of renal cell carcinoma from literature data and explores the future direction of the treatment.

Molecular target therapy for synovial sarcoma

2005 ◽  
Vol 1 (6) ◽  
pp. 805-812 ◽  
Author(s):  
Chikako Fukukawa ◽  
Yusuke Nakamura ◽  
Toyomasa Katagiri
Keyword(s):  
Synovial Sarcoma ◽  
Target Therapy ◽  
Molecular Target ◽  
Molecular Target Therapy

A case of advanced melanoma treated with molecular target therapy and immune checkpoint inhibitors

Skin Cancer ◽  
2017 ◽  
Vol 31 (3) ◽  
pp. 222-226
Author(s):  
Aya TANAKA ◽  
Atsushi TANAMURA ◽  
Kuniko IKINAGA ◽  
Yukinobu NAKAGAWA ◽  
Eiji KIYOHARA ◽  
...  
Keyword(s):  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Target Therapy ◽  
Molecular Target ◽  
Advanced Melanoma ◽  
Molecular Target Therapy
Sign in / Sign up

Export Citation Format

Share Document